CHICAGO HIGHLIGHTS 2024 – MELANOMA ROUNDTABLE DISCUSSION: Neoadjuvant/Adjuvant
OR
Chair
Dr. Vanessa Bernstein
Panelists
Prof. Caroline Robert
Dr. Marcus Butler
Studies/trials discussed:
- The NADINA trial: A multicenter, randomised, phase 3 trial comparing the efficacy of neoadjuvant ipilimumab plus nivolumab with standard adjuvant nivolumab in macroscopic resectable stage III melanoma.
- Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD). (COMBI-AD)
- Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial
- Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial
- Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
- Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
